Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

More Action, Less Plan? House Keeps Pressure On US FDA Over ALS Drugs

26 Jul 2022

• By Michael McCaughan

Congress and ALS — Congressional leaders are showing their support for ALS products • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock images

Related Content

US FDA Doesn’t Need Conditional Approval Pathway, Cavazzoni Tells House Committee

30 Jul 2021

House User Fee Mark-Up: Few Tweaks, But Concerns About ALS And Accelerated Approval

19 May 2022

Will Amylyx’s ALS Drug Benefit From US FDA’s Aduhelm Experience?

05 Jul 2022

US FDA’s ALS Science Strategy Includes Near-Term Rare Neurodegenerative Disease Task Force

24 Jun 2022

Related Companies

Amylyx Pharmaceuticals, Inc.

Additional Topics

United States Drug Approval Standards Drug Review Politics Regulation Neurology BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.